Browsing Tag
belzutifan
3 posts
Merck’s KEYTRUDA + WELIREG combo shows major disease-free survival benefit in clear cell renal cell carcinoma after surgery
Find out how Merck’s KEYTRUDA + WELIREG combo improved disease-free survival after kidney cancer surgery and what it means for the oncology market.
Merck and Eisai announce major win as Welireg plus Lenvima delays progression in advanced renal cell carcinoma
Find out how Merck and Eisai’s Welireg + Lenvima combo redefines kidney cancer care after immunotherapy and what this major Phase 3 win means for investors.
Merck’s WELIREG meets primary endpoint of PFS in Phase 3 RCC trial
Global pharmaceutical leader Merck has announced that WELIREG (belzutifan), its pioneering oral HIF-2α inhibitor, has achieved a critical…